In resectable NSCLC 🫁, 18-month distant metastasis–free survival rate was ~80% with perioperative chemoimmunotherapy, per retrospective study. Outcomes similar across neoadjuvant/adjuvant use.
Study by @ADesaiMD et al
🔗https://t.co/J9lWhU2wcv
#LCSM#NSCLC#Immunotherapy